Seeking Healthcare in Mexico: What International Patients Should Know About Regulation and Quality

For anyone considering healthcare outside the U.S., there is usually one question behind all the others:

How does this compare to the standards I’m used to—and am I sacrificing quality for cost or access?

It is a reasonable concern. Traveling for healthcare may offer advantages such as greater access, shorter wait times and a more personalized experience, but those benefits should never require compromising on regulatory oversight or clinical rigor.

In Mexico, healthcare is supported by a formal federal regulatory framework led by COFEPRIS, the Federal Commission for the Protection against Sanitary Risks.

And recently, that regulatory system has been undergoing significant international scrutiny.

Mexico’s health regulator is being evaluated against global standards

From August 31 to September 4, 2026, experts from the World Health Organization (WHO), accompanied by the Pan American Health Organization (PAHO) and the European Union, conducted a technical visit to COFEPRIS as part of an evaluation using the WHO Global Benchmarking Tool (GBT). (Gobierno de México)

The GBT is not simply an informal review.

WHO uses it to assess the maturity of national regulatory systems, including their legal frameworks, organizational structures, resources and regulatory processes. (Organización Mundial de la Salud)

The broader goal is to determine how effectively a regulator performs functions related to the quality, safety and efficacy of medicines, vaccines and other health products. (Paho)

This matters because the same WHO framework forms part of the pathway toward becoming a WHO Listed Authority (WLA)—a designation reserved for regulatory authorities that demonstrate a high level of regulatory capability and performance. (Organización Mundial de la Salud)

For context, the U.S. Food and Drug Administration was designated a WHO Listed Authority in 2024. (Organización Mundial de la Salud)

COFEPRIS has not reached FDA-equivalent or WLA status at this time. What the current evaluation does provide is something important for international patients: independent evidence that Mexico’s regulator is actively measuring and strengthening its system against internationally recognized benchmarks.

Mexico and the FDA are also working together

In 2026, COFEPRIS Commissioner Víctor Hugo Borja met with representatives of the U.S. FDA led by Mark Abdoo, the FDA’s Associate Commissioner for Global Policy and Strategy. COFEPRIS has described the meeting as part of its broader work around international regulatory cooperation. (LinkedIn)

The FDA and Mexican authorities also have established areas of collaboration, including food-safety initiatives and regulatory cooperation between the two countries. (U.S. Food and Drug Administration)

None of this means the two regulatory systems are identical. It does, however, help place Mexican healthcare within a broader international regulatory context rather than treating care in Mexico as something operating outside recognized oversight.

What does this mean when choosing a clinic in Mexico?

National regulation is only part of the equation.

International patients should still ask the same questions they would ask when choosing a provider at home:

Who regulates the clinic? Are its partners and laboratories regulated? Can the provider document its licenses and credentials? What standards are used for the treatments, products and laboratories involved in your care?

At Lonvida, we believe patients should be able to get clear answers to those questions.

Lonvida operates under COFEPRIS License No. 25-TR-09-016-0001 and works exclusively with COFEPRIS-regulated partners and laboratories. Click here to see all our partner's license information.

For international patients, that means greater access and a streamlined healthcare experience do not have to come at the expense of understanding who stands behind the care you receive.

Less red tape. Not less scrutiny.

Choosing healthcare abroad should not mean lowering your expectations. Mexico can offer international patients a different healthcare experience—one with easier access, personalized coordination and fewer administrative barriers—but the decision should still be based on credentials, regulation and transparency.

If you are considering care in Mexico, Lonvida’s International Patient Program can help you understand your options before traveling, coordinate your experience and answer questions about our facilities, medical team, regulatory status and treatment process.

To learn more, contact our Longevity Concierge through or website chat or directly through WhatsApp at +52 55 7906 4445